Parthasarathi Bhattacharyya
Research Subjects
Parthasarathi Bhattacharyya has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Dipanjan Saha
Department of General Pulmonology, Institute of Pulmocare and Research, Kolkata, West Bengal, India
15 shared publicationsSayoni Sengupta
Department of Pulmonary Circulation Institute of Pulmocare and Research, Kolkata, West Bengal, India
10 shared publicationsDebkanya Dey
Institute of Pulmocare & Research, Department of Airway Disease, Institute of Pulmocare and Research, Kolkata, India
9 shared publicationsMintu Paul
Department of General Pulmonology, Institute of Pulmocare and Research, Kolkata, West Bengal, India
8 shared publicationsAvishek Kar
Department of General Pulmonary Medicine, Institute of Pulmocare and Research, Kolkata, West Bengal, India
6 shared publicationsRatna Dey
Research Assistant, Institute of Pulmocare and Research, Kolkata, India
6 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Ever-smoker and never-smoker COPD from the prism of salbutamol and glycopyrronium responsiveness: an appraisal
- 27 October 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Open AccessEver-smoker and never-smoker COPD from the prism of salbutamol and glycopyrronium responsiveness: an appraisal
- 13 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 264
Treatable trait in COPD: is LVDD the potential next?
- 13 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 264
Treatable trait in COPD: is LVDD the potential next?
- Open Access
- 24 June 2026
- Published by Wolters Kluwer Health in Lung India
- Vol. 43 (4) , 399-403
Normal spirometry with high and asthma-defining bronchodilator responsiveness: An appraisal from real-life data
Background: Spirometric exercise in symptomatic patients (with/without suspicion of airflow obstruction) often ends with results showing normal pre-bronchodilator values. Methods: We screened two different populations with prospectively archived spirometry, consisting of a) clinical suspicion of OAD (obstructive airway disease) and b) all other indications without any suspicion of OAD. Both populations underwent BDR (bronchodilator responsiveness) with salbutamol. We screened out the patients that displayed ‘normal spirometry’ [pre-bronchodilator (FEV1/FVC > 0.7 with FEV1 and FVC > 80%] and further looked for the presence of high (≥200 mL alone) or asthma-defining (>200 mL and 12%) BDR in them. Results: The two sets included 1019 and 3060 subjects in patients with or without suspected OAD. They showed the presence of 11.87% (121/1019) and 27.71% (848/3060) of normal spirometry. In the first set, 24.7% ( n = 30) and 17.35% ( n = 21), and in the second set, 12.26% ( n = 104) and 4.7% ( n = 40) patients had high (>200 mL) or asthma-defining (200 mL plus 12%) BDR. Thus, the asthma-defining BDR is present in 2.06% (21/1019) and 1.30% (40/3060) of patients with or without suspected OAD with normal pre-bronchodilator spirometry. The prevalence of isolated high BDR (200 mL) was present in 0.88% [9 (30–21) out of 1019] and 2.09% [ n = 64 (135–54)/3060] of them. Conclusion: Some patients with respiratory symptoms with or without suspicion of airflow obstruction display pre-bronchodilator normal spirometry, and some of them demonstrate high or asthma-defining bronchodilator responsiveness. Performing BDR should be a routine in respiratory practice.
- 24 June 2026
- Published by Wolters Kluwer Health in Lung India
- Vol. 43 (4) , 399-403
Open AccessNormal spirometry with high and asthma-defining bronchodilator responsiveness: An appraisal from real-life data
Background: Spirometric exercise in symptomatic patients (with/without suspicion of airflow obstruction) often ends with results showing normal pre-bronchodilator values. Methods: We screened two different populations with prospectively archived spirometry, consisting of a) clinical suspicion of OAD (obstructive airway disease) and b) all other indications without any suspicion of OAD. Both populations underwent BDR (bronchodilator responsiveness) with salbutamol. We screened out the patients that displayed ‘normal spirometry’ [pre-bronchodilator (FEV1/FVC > 0.7 with FEV1 and FVC > 80%] and further looked for the presence of high (≥200 mL alone) or asthma-defining (>200 mL and 12%) BDR in them. Results: The two sets included 1019 and 3060 subjects in patients with or without suspected OAD. They showed the presence of 11.87% (121/1019) and 27.71% (848/3060) of normal spirometry. In the first set, 24.7% ( n = 30) and 17.35% ( n = 21), and in the second set, 12.26% ( n = 104) and 4.7% ( n = 40) patients had high (>200 mL) or asthma-defining (200 mL plus 12%) BDR. Thus, the asthma-defining BDR is present in 2.06% (21/1019) and 1.30% (40/3060) of patients with or without suspected OAD with normal pre-bronchodilator spirometry. The prevalence of isolated high BDR (200 mL) was present in 0.88% [9 (30–21) out of 1019] and 2.09% [ n = 64 (135–54)/3060] of them. Conclusion: Some patients with respiratory symptoms with or without suspicion of airflow obstruction display pre-bronchodilator normal spirometry, and some of them demonstrate high or asthma-defining bronchodilator responsiveness. Performing BDR should be a routine in respiratory practice.
- Open Access
- 30 April 2026
- Published by Wolters Kluwer Health in Lung India
- Vol. 43 (3) , 258-265
The precision bronchodilator therapy in airflow limitation with asthma defining reversibility: An appraisal through pharmaco-responsiveness-based real-world observation
Background: The advent of glycopyrronium responsiveness (GPR) has opened an avenue for precision bronchodilator therapy in asthmatics. Methods: We noted 2-Chair test (2CT) and spirometry with salbutamol bronchodilator-responsiveness (BDR) followed immediately by GPR in a cohort of asthmatics in an open, randomised observation. We treated (GINA stage-2 and 3) asthmatics with long-acting β2-agonist plus inhaled-corticosteroid (LABA-ICS) for salbutamol-BDR and with inhaled triple therapy (LABA-LAMA-ICS) for those having BDR and GPR. We compared the spirometry and 2-chair tests statistically between the initial and the follow-up status. Results: The two groups (30 each) were similar in demographic (age, body mass index), spirometric, and 2CT parameters. Post treatment (346.2 ± 242.3 and 390.2 ± 212.6 days for BDR and BDR+GPR-positive cases), both the groups improved universally. The GPR-positive triple drug treated group had similar change (215.7 ± 346.1 vs. 161.3 ± 318.7, P = 0.1578) in trough FEV1 but had a significantly higher value for post-salbutamol (449.0 ± 209.0 vs. 348.7 ± 282.2; P = 0.0201) and post-GP (531.7 ± 248.7 vs. 348.7 ± 282.2; P = 0.0015) FEV1 values on follow-up. The patients accepted the triple therapy universally without any serious adverse events. The two groups had similar number of mild exacerbations. Conclusions: The pharmaco-responsiveness based add-on LAMA is seen to improve lung function of asthma in early GINA stages with parallel, though not significant, changes in the post-exercise recovery response (Desat-max in 2CT). The observation demands attention to consider upfront prescription of LAMA based on universal performance of GP responsiveness in asthma.
- 30 April 2026
- Published by Wolters Kluwer Health in Lung India
- Vol. 43 (3) , 258-265
Open AccessThe precision bronchodilator therapy in airflow limitation with asthma defining reversibility: An appraisal through pharmaco-responsiveness-based real-world observation
Background: The advent of glycopyrronium responsiveness (GPR) has opened an avenue for precision bronchodilator therapy in asthmatics. Methods: We noted 2-Chair test (2CT) and spirometry with salbutamol bronchodilator-responsiveness (BDR) followed immediately by GPR in a cohort of asthmatics in an open, randomised observation. We treated (GINA stage-2 and 3) asthmatics with long-acting β2-agonist plus inhaled-corticosteroid (LABA-ICS) for salbutamol-BDR and with inhaled triple therapy (LABA-LAMA-ICS) for those having BDR and GPR. We compared the spirometry and 2-chair tests statistically between the initial and the follow-up status. Results: The two groups (30 each) were similar in demographic (age, body mass index), spirometric, and 2CT parameters. Post treatment (346.2 ± 242.3 and 390.2 ± 212.6 days for BDR and BDR+GPR-positive cases), both the groups improved universally. The GPR-positive triple drug treated group had similar change (215.7 ± 346.1 vs. 161.3 ± 318.7, P = 0.1578) in trough FEV1 but had a significantly higher value for post-salbutamol (449.0 ± 209.0 vs. 348.7 ± 282.2; P = 0.0201) and post-GP (531.7 ± 248.7 vs. 348.7 ± 282.2; P = 0.0015) FEV1 values on follow-up. The patients accepted the triple therapy universally without any serious adverse events. The two groups had similar number of mild exacerbations. Conclusions: The pharmaco-responsiveness based add-on LAMA is seen to improve lung function of asthma in early GINA stages with parallel, though not significant, changes in the post-exercise recovery response (Desat-max in 2CT). The observation demands attention to consider upfront prescription of LAMA based on universal performance of GP responsiveness in asthma.
- 14 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 255, 108779
Lipid biomarkers for differentiating asthma-COPD overlap: Insights from LC-MS-based lipidomics
- 14 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 255, 108779
Lipid biomarkers for differentiating asthma-COPD overlap: Insights from LC-MS-based lipidomics
- Open Access
- 1 November 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 3725-3735
Appreciation of Increased Pulmonary Vascular Resistance from the Maximum Desaturation in 2-Chair Test: An Appraisal
Introduction: The desat max of 2-chair test, claimed to have identified the sildenafil responsiveness in COPD-PH (pulmonary hypertension), should represent high PVR (pulmonary vascular resistance). Methods: Hemodynamically diagnosed PH in CLD (chronic lung disease)-patients were analyzed statistically and divided into two groups on high or low PVR (> 2 and ≤ 2 Wood units) to judge the power of the desat-max of 2-chair test differentiating them. Co-relationship of desat-max was sought with different spirometric, Doppler-echocardiographic, and RHC (right heart catheterization) derived parameters as TPG (trans-pulmonary gradient), PVR, mPAP (mean pulmonary pressure) and PCWP (pulmonary capillary wedge pressure). Further, the specificity and sensitivity of variable desat-max values were calculated and high PVR and a VIP plot was drawn with all available variables to see their impact on PVR compared to desat-max. Results: We included 57 patients of CLD-PH consisting of COPD (n=26), chronic asthma (n=9), ILD (n=7), and miscellaneous diseases (n=15). When divided on high or low PVR, the two groups (n=39 and 18) stood similar in demographic, spirometric, and Doppler-echocardiography measurements. However, they differed in desat-max (− 8.76± 4.90 and − 3.61± 1.94; P< 0.0001) and in RHC derived mean-PVR (4.25± 2.97 vs 1.20± 0.53; P< 0.0001), mean-TPG (12.86± 4.84 vs 5.11± 2.78; P< 0.0001), cardiac output (3.77± 1.07 and 4.29± 1.15; P=0.02). The calculated best cut-off desat-max (> 4.5%) could identify high PVR with 72.22% sensitivity and 79.40% specificity with adjusted odds ratio of 19.55. The desat-max correlated best with RHC-measured PVR (r=0.56) but not with PCWP (r=0.09). Conclusion: Desat-max of 2-chair test appears indicative of high PVR in CLD-PH. The revelation merits further research.
- 1 November 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 3725-3735
Open AccessAppreciation of Increased Pulmonary Vascular Resistance from the Maximum Desaturation in 2-Chair Test: An Appraisal
Introduction: The desat max of 2-chair test, claimed to have identified the sildenafil responsiveness in COPD-PH (pulmonary hypertension), should represent high PVR (pulmonary vascular resistance). Methods: Hemodynamically diagnosed PH in CLD (chronic lung disease)-patients were analyzed statistically and divided into two groups on high or low PVR (> 2 and ≤ 2 Wood units) to judge the power of the desat-max of 2-chair test differentiating them. Co-relationship of desat-max was sought with different spirometric, Doppler-echocardiographic, and RHC (right heart catheterization) derived parameters as TPG (trans-pulmonary gradient), PVR, mPAP (mean pulmonary pressure) and PCWP (pulmonary capillary wedge pressure). Further, the specificity and sensitivity of variable desat-max values were calculated and high PVR and a VIP plot was drawn with all available variables to see their impact on PVR compared to desat-max. Results: We included 57 patients of CLD-PH consisting of COPD (n=26), chronic asthma (n=9), ILD (n=7), and miscellaneous diseases (n=15). When divided on high or low PVR, the two groups (n=39 and 18) stood similar in demographic, spirometric, and Doppler-echocardiography measurements. However, they differed in desat-max (− 8.76± 4.90 and − 3.61± 1.94; P< 0.0001) and in RHC derived mean-PVR (4.25± 2.97 vs 1.20± 0.53; P< 0.0001), mean-TPG (12.86± 4.84 vs 5.11± 2.78; P< 0.0001), cardiac output (3.77± 1.07 and 4.29± 1.15; P=0.02). The calculated best cut-off desat-max (> 4.5%) could identify high PVR with 72.22% sensitivity and 79.40% specificity with adjusted odds ratio of 19.55. The desat-max correlated best with RHC-measured PVR (r=0.56) but not with PCWP (r=0.09). Conclusion: Desat-max of 2-chair test appears indicative of high PVR in CLD-PH. The revelation merits further research.
- Open Access
- 30 August 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-9
The intra-breath changes of reactance at low frequency in impulse oscillometry: differentiating obstructive airway disease and Interstitial Lung Disease
Impulse Oscillometry (IOS) helps understanding the mechanical properties of the respiratory system. Evaluating its role in distinguishing Obstructive Airway Disease (OAD) from Restrictive Lung Disease (RLD) remains underexplored. We included the consecutive patients of both OAD (asthma and COPD), ILD (representing RLD) observing guideline recommendations and a cohort of ‘healthy’ subjects (asymptomatic, no disease clinico-radiologically and on spirometry). They underwent spirometry and impulse oscillometry concurrently on the same sitting. The comparison between the three groups included IOS derived R5, R10, R15, R20, R5-10, R5-15, R5-20, R10-20, X5, Rin5 (R5 inspiration), Rex5 (R5 expiration), Xin5 (X5 inspiration) and Xex5 (X5 expiration), Fres and AX. We proposed Δintrabreath-X5 (Xin5-Xex5) and a ‘reactance variance index’ (RVI) [(Xin5-Xex5)/Xex5 × 100] in the effort. Those showing highly significant difference (p ≤ 0.0001) were analysed with the ROC curves to determine the best differentiating values. We included 104 OAD (COPD: 53, Asthma: 51), 75 RLDs and 43 healthy controls. Multiple resistance (R5, R5-10, R5-15, R5-20, and Rex5 Xex5) and reactance related (X5, Fres and AX) parameters displayed significant difference (p < 0.0001). The Xex5 and R5 turned out to be the best discriminators, with areas under the curve of 0.9244 and 0.9292, showing sensitivities of 88.57% and 85.85%, and specificities of 95.35% and 100%, respectively, using cut-off values of -2.49 and 5.04 in differentiating OAD from healthy subjects. Of the resistance factors (R5, R10, R15, R20, R5-15, R5-20, R-in-5) significantly differed between ILD and healthy cohorts; the R5 had the highest discriminating power (sensitivity of 64% and specificity of 100% to differentiate them. The Δintrabreath-X5 could best distinguish ILD from OAD with 88.06% sensitivity and 80.95% specificity, closely followed by Xin5/Xex5 and the RVI. IOS can acceptably distinguish OAD from ILD using Δintrabreath-X5. The observation demands further validation.
- 30 August 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-9
Open AccessThe intra-breath changes of reactance at low frequency in impulse oscillometry: differentiating obstructive airway disease and Interstitial Lung Disease
Impulse Oscillometry (IOS) helps understanding the mechanical properties of the respiratory system. Evaluating its role in distinguishing Obstructive Airway Disease (OAD) from Restrictive Lung Disease (RLD) remains underexplored. We included the consecutive patients of both OAD (asthma and COPD), ILD (representing RLD) observing guideline recommendations and a cohort of ‘healthy’ subjects (asymptomatic, no disease clinico-radiologically and on spirometry). They underwent spirometry and impulse oscillometry concurrently on the same sitting. The comparison between the three groups included IOS derived R5, R10, R15, R20, R5-10, R5-15, R5-20, R10-20, X5, Rin5 (R5 inspiration), Rex5 (R5 expiration), Xin5 (X5 inspiration) and Xex5 (X5 expiration), Fres and AX. We proposed Δintrabreath-X5 (Xin5-Xex5) and a ‘reactance variance index’ (RVI) [(Xin5-Xex5)/Xex5 × 100] in the effort. Those showing highly significant difference (p ≤ 0.0001) were analysed with the ROC curves to determine the best differentiating values. We included 104 OAD (COPD: 53, Asthma: 51), 75 RLDs and 43 healthy controls. Multiple resistance (R5, R5-10, R5-15, R5-20, and Rex5 Xex5) and reactance related (X5, Fres and AX) parameters displayed significant difference (p < 0.0001). The Xex5 and R5 turned out to be the best discriminators, with areas under the curve of 0.9244 and 0.9292, showing sensitivities of 88.57% and 85.85%, and specificities of 95.35% and 100%, respectively, using cut-off values of -2.49 and 5.04 in differentiating OAD from healthy subjects. Of the resistance factors (R5, R10, R15, R20, R5-15, R5-20, R-in-5) significantly differed between ILD and healthy cohorts; the R5 had the highest discriminating power (sensitivity of 64% and specificity of 100% to differentiate them. The Δintrabreath-X5 could best distinguish ILD from OAD with 88.06% sensitivity and 80.95% specificity, closely followed by Xin5/Xex5 and the RVI. IOS can acceptably distinguish OAD from ILD using Δintrabreath-X5. The observation demands further validation.
- Open Access
- 27 June 2025
- Published by Wolters Kluwer Health in Lung India
- Vol. 42 (4) , 322-329
Exploring the possibility of a predictable precision therapy of COPD with inclusion of glycopyrronium responsiveness: A real-world experience
Background: The advent of glycopyrronium responsiveness has opened the prospect of selective responsiveness-based prescription of bronchodilators-β2-agonists or anti-muscarinic agents (AMA) for COPD. Such a concept needs ratification through clinical trials. Methods: Stable COPD patients [post-bronchodilator FEV1/FVC 1-improvement] after salbutamol before universal prescription of LABA-LAMA ± ICS as per guideline recommendation. At real-world follow-up, we noted the adverse and serious adverse events (exacerbations and hospitalizations) and, whenever possible, repeated spirometry in the similar fashion. Based on the initial glycopyrronium responsiveness, we divided the patients into glycopyrronium-sensitive and non-sensitive groups and compared the impact of treatment between them using spirometric variables (FEV1, FVC, FEV1/FVC and FEF25-75). We compared the ‘trough’-FEV1 and ‘total’-FEV1 (difference from the initial pre-bronchodilator to final post-dual-bronchodilator values) along with the frequency of exacerbation and hospitalization in each group. Results: The glycopyrronium-responsive and non-responsive groups (n = 30 for each) were similar demographically and on initial spirometry (pre-bronchodilator and post-salbutamol values). They received treatment for 162.4 ± 134.8 and 212 ± 118.1 days, respectively. The glycopyrronium-sensitive patients displayed significant improvement in both trough-FEV1 [0.17 ± 0.29 vs. 0.02 ± 0.2; (P = 0.0308)], total-FEV1 [0.32 ± 0.29 vs. 0.17 ± 0.21; (P = 0.0273) litres], in addition to trough FEF25-75 (P = 0.0204), total FEV1/FVC (0.0174) and total FEF25-75 (P = 0.0322). The exacerbations (P = 0.0056) were significantly lower in glycopyrronium-responsive patients. Conclusion: The glycopyrronium-responsive COPD patients show a significantly better overall improvement including the significant change in trough and total FEV1 with significantly reduced exacerbations in the real-world observation. The revelation demands more research.
- 27 June 2025
- Published by Wolters Kluwer Health in Lung India
- Vol. 42 (4) , 322-329
Open AccessExploring the possibility of a predictable precision therapy of COPD with inclusion of glycopyrronium responsiveness: A real-world experience
Background: The advent of glycopyrronium responsiveness has opened the prospect of selective responsiveness-based prescription of bronchodilators-β2-agonists or anti-muscarinic agents (AMA) for COPD. Such a concept needs ratification through clinical trials. Methods: Stable COPD patients [post-bronchodilator FEV1/FVC 1-improvement] after salbutamol before universal prescription of LABA-LAMA ± ICS as per guideline recommendation. At real-world follow-up, we noted the adverse and serious adverse events (exacerbations and hospitalizations) and, whenever possible, repeated spirometry in the similar fashion. Based on the initial glycopyrronium responsiveness, we divided the patients into glycopyrronium-sensitive and non-sensitive groups and compared the impact of treatment between them using spirometric variables (FEV1, FVC, FEV1/FVC and FEF25-75). We compared the ‘trough’-FEV1 and ‘total’-FEV1 (difference from the initial pre-bronchodilator to final post-dual-bronchodilator values) along with the frequency of exacerbation and hospitalization in each group. Results: The glycopyrronium-responsive and non-responsive groups (n = 30 for each) were similar demographically and on initial spirometry (pre-bronchodilator and post-salbutamol values). They received treatment for 162.4 ± 134.8 and 212 ± 118.1 days, respectively. The glycopyrronium-sensitive patients displayed significant improvement in both trough-FEV1 [0.17 ± 0.29 vs. 0.02 ± 0.2; (P = 0.0308)], total-FEV1 [0.32 ± 0.29 vs. 0.17 ± 0.21; (P = 0.0273) litres], in addition to trough FEF25-75 (P = 0.0204), total FEV1/FVC (0.0174) and total FEF25-75 (P = 0.0322). The exacerbations (P = 0.0056) were significantly lower in glycopyrronium-responsive patients. Conclusion: The glycopyrronium-responsive COPD patients show a significantly better overall improvement including the significant change in trough and total FEV1 with significantly reduced exacerbations in the real-world observation. The revelation demands more research.
- Open Access
- 26 March 2025
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 161 (2) , 174-181
The desat-max in 2-chair test appears to be a worthwhile parameter to identify sickness: An appraisal
Background & objectives: The 2-chair test (2CT) has recently been proposed as a cardiopulmonary reserve-specific assessment of post-exercise recovery response. The objective of this study was to find out the most appropriate parameter of 2CT to categorically differentiate between ‘normal’ and symptomatic diseased population. Methods: In a prospective manner, we recruited a random cohort of symptomatic patients attending our outpatient department (OPD) with different respiratory diseases. We also selected another cohort of ‘normal’ persons from the willing attendants of the patients who had no symptoms and revealed no abnormality on chest X-ray and spirometry. Persons belonging to both groups were requested to mark their ‘sickness’ on a scale of 0 to 10 (‘0’ meaning none and ‘10’ meaning maximum possible) under the PPSS (patient-perceived sickness score) and were subjected to perform 2CT. All the test variables related to pulse rate and peripheral capillary oxygen saturation (SpO2) changes were noted for both groups. The ‘symptomatic’ and ‘normal’ persons were compared based on the 2CT variables to find the well-performing discriminatory parameter. Results: The comparison of 2CT variables of 419 patients and 30 ‘normal’ controls revealed that the PR change max, maximum SpO2, minimum-SpO2, and desat-max can significantly differentiate between the two. However, the desat-max correlated to the PPSS best. The VIP plot, primary component analysis, and pattern-hunter representation further substantiated this. Interpretation & conclusions: The desat-max appears to be a sensitive parameter to differentiate the normal from the symptomatic diseased population. Further research in this area is warranted.
- 26 March 2025
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 161 (2) , 174-181
Open AccessThe desat-max in 2-chair test appears to be a worthwhile parameter to identify sickness: An appraisal
Background & objectives: The 2-chair test (2CT) has recently been proposed as a cardiopulmonary reserve-specific assessment of post-exercise recovery response. The objective of this study was to find out the most appropriate parameter of 2CT to categorically differentiate between ‘normal’ and symptomatic diseased population. Methods: In a prospective manner, we recruited a random cohort of symptomatic patients attending our outpatient department (OPD) with different respiratory diseases. We also selected another cohort of ‘normal’ persons from the willing attendants of the patients who had no symptoms and revealed no abnormality on chest X-ray and spirometry. Persons belonging to both groups were requested to mark their ‘sickness’ on a scale of 0 to 10 (‘0’ meaning none and ‘10’ meaning maximum possible) under the PPSS (patient-perceived sickness score) and were subjected to perform 2CT. All the test variables related to pulse rate and peripheral capillary oxygen saturation (SpO2) changes were noted for both groups. The ‘symptomatic’ and ‘normal’ persons were compared based on the 2CT variables to find the well-performing discriminatory parameter. Results: The comparison of 2CT variables of 419 patients and 30 ‘normal’ controls revealed that the PR change max, maximum SpO2, minimum-SpO2, and desat-max can significantly differentiate between the two. However, the desat-max correlated to the PPSS best. The VIP plot, primary component analysis, and pattern-hunter representation further substantiated this. Interpretation & conclusions: The desat-max appears to be a sensitive parameter to differentiate the normal from the symptomatic diseased population. Further research in this area is warranted.
- Open Access
- 23 December 2024
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 160 (5) , 439-447
On-the-spot spirometry & combined salbutamol & glycopyrronium reversibility testing in obstructive airway disease: A real-world appraisal
Background & objectives: Spirometric glycopyrronium responsiveness, a new advent, needs to be examined at in terms of degree and frequency in different obstructive-airway diseases diagnosed in real world practise. Methods: Serial and willing symptomatic affected individuals of suspected airway disease underwent a pragmatic post-consultation spirometry-protocol on the same day with salbutamol followed by glycopyrronium bromide. The diagnosis of asthma (FEV1-reversibility ≥ 200 ml + 12%), chronic obstructive pulmonary disease (COPD) (FEV1/FVC1-reversibility <200 ml and/or 12%), and ‘unclassified’ (neither asthma nor COPD) were determined on post-salbutamol changes. The performances of the two classes of bronchodilators were compared on FVC, FEV1/FVC, FEV1, and FEF-25-75 while the relative frequency of significant responsiveness for salbutamol (≥200 ml) and glycopyrronium (≥100 ml) were noted. Results: Fifteen hundred and eighty study participants consisting of asthma (n=329; 21%), COPD (n=641; 40%), and ‘unclassified’ (n=610; 39%) were included. Both salbutamol and glycopyrronium had demonstrated improvement across the spirometric parameters. The salbutamol responsiveness was statistically significant in all but COPD in terms of absolute values of FEV1, FEV1/FVC, and FEF25-75 and the glycopyrronium responsiveness was significant in all plus COPD in FVC, FEV1, and FEF25-75 values. While all the asthmatics, 9.83 per cent of ‘unclassified’ study participants, and none of the COPD affected individuals had significant FEV1 responsiveness to salbutamol, the glycopyrronium responsiveness for the three conditions were 38.3, 40.25 and 24.26 per cent, respectively. The combined reversibility for asthma, COPD, and unclassified were 401.5±173.9, 119.5±109.3, and 158.7±136.3 ml, respectively. Interpretation & conclusions: Spirometry with serial salbutamol and glycopyrronium responsiveness may prove helpful in identifying syndromic diagnosis and choosing the bronchodilator treatment of airway diseases.
- 23 December 2024
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 160 (5) , 439-447
Open AccessOn-the-spot spirometry & combined salbutamol & glycopyrronium reversibility testing in obstructive airway disease: A real-world appraisal
Background & objectives: Spirometric glycopyrronium responsiveness, a new advent, needs to be examined at in terms of degree and frequency in different obstructive-airway diseases diagnosed in real world practise. Methods: Serial and willing symptomatic affected individuals of suspected airway disease underwent a pragmatic post-consultation spirometry-protocol on the same day with salbutamol followed by glycopyrronium bromide. The diagnosis of asthma (FEV1-reversibility ≥ 200 ml + 12%), chronic obstructive pulmonary disease (COPD) (FEV1/FVC1-reversibility <200 ml and/or 12%), and ‘unclassified’ (neither asthma nor COPD) were determined on post-salbutamol changes. The performances of the two classes of bronchodilators were compared on FVC, FEV1/FVC, FEV1, and FEF-25-75 while the relative frequency of significant responsiveness for salbutamol (≥200 ml) and glycopyrronium (≥100 ml) were noted. Results: Fifteen hundred and eighty study participants consisting of asthma (n=329; 21%), COPD (n=641; 40%), and ‘unclassified’ (n=610; 39%) were included. Both salbutamol and glycopyrronium had demonstrated improvement across the spirometric parameters. The salbutamol responsiveness was statistically significant in all but COPD in terms of absolute values of FEV1, FEV1/FVC, and FEF25-75 and the glycopyrronium responsiveness was significant in all plus COPD in FVC, FEV1, and FEF25-75 values. While all the asthmatics, 9.83 per cent of ‘unclassified’ study participants, and none of the COPD affected individuals had significant FEV1 responsiveness to salbutamol, the glycopyrronium responsiveness for the three conditions were 38.3, 40.25 and 24.26 per cent, respectively. The combined reversibility for asthma, COPD, and unclassified were 401.5±173.9, 119.5±109.3, and 158.7±136.3 ml, respectively. Interpretation & conclusions: Spirometry with serial salbutamol and glycopyrronium responsiveness may prove helpful in identifying syndromic diagnosis and choosing the bronchodilator treatment of airway diseases.